Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq WT vs TLE3KO ( treated with AR inhibitor)

ABSTRACT: RNA-seq WT vs TLE3KO ( treated with AR inhibitor)

PROVIDER: PRJNA468819 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7133512.fastq.gz	Fastqsanger.gz
	SRR7133513.fastq.gz	Fastqsanger.gz
	SRR7133514.fastq.gz	Fastqsanger.gz

Items per page:

1 - 3 of 3

Similar Datasets

RNA-seq WT vs TLE3KO ( treated with AR inhibitor)

Project description:Transcriptome analysis of LNCaP control and TLE3 KO cells treated with AR inhibitor

2021-05-08 | GSE114187 | GEO

Transcriptome profiling of castration resistant prostate cancer cells treated with novel AR N-terminal inhibitor

Project description:This study aimed at exploring how would the novel AR N-terminal inhibitor affect the androgen receptor (AR) transcriptome, especially a subset of genes that are uniquely upregulated by AR-V7 in castration resistant prostate cancer cells. We performed next-generation sequencing-based gene expression profiling (RNA-sequencing) on the castration-resistant prostate cancer celll line LNCaP-95. LNCaP-95 expresses high level of endogeneous AR-V7, and also acquired an adaptive shift towards AR-V7-mediated AR signaling activity. Beside regulating the transcription of a subset of canonical wildtype AR genes, AR-V7 also mediates a distinct transcriptional program that is independent of wildtype AR in LNCaP-95. In this experiment, LNCaP-95 cells were treated with vehicle control or the AR-N terminal inhibitor SC912. The subsequent AR transcriptomic change following compound treatment, especially the AR-V7 unique genes were assessed by RNA-seq.

2024-04-30 | GSE253122 | GEO

A. thaliana WT and ICT1 mutant treated vs. non treated with I3C

Project description:A. thaliana WT and ICT1 mutant treated vs. non treated with I3C

| PRJNA672150 | ENA

UPAB1 secretome analysis of hlyD1 vs hlyD2 vs Wt.

Project description:A. baumannii UPAB1 secretome analysis of hlyD1 vs Wt and hlyD2 vs Wt.

2021-08-09 | PXD024736 | Pride

PTPN2 knockout vs WT

Project description:PTPN2 knockout vs WT

| PRJNA871237 | ENA

Sectection analysis of A. baumannii (WT vs gspD vs HlyD1 vs HlyD2 vs RTX)

Project description:Comparsion of the secretome of A. baumannii (WT vs gspD vs HlyD1 vs HlyD2 vs RTX)

2022-04-06 | PXD030460 | Pride

Rice root: Control vs auxin transport inhibitor N-1-naphthylphthalamic (NPA) treatment WT vs iaa13 mutant.

Project description:Rice root: Control vs auxin transport inhibitor N-1-naphthylphthalamic (NPA) treatment WT vs iaa13 mutant.

| PRJNA534059 | ENA

A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities.

Project description:Development of a novel CRISPR-derived cell line which is a derivative of CWR22Rv1 cells, called CWR22Rv1-AR-EK, that has lost expression of FL-AR, but retains all endogenous AR-Vs. AR-Vs act unhindered by loss of FL-AR to drive cell growth and expression of androgenic genes. Global transcriptomics demonstrate that AR-Vs drive expression of a cohort of DNA damage response genes and depletion of AR-Vs sensitizes cells to ionizing radiation.

2019-02-09 | GSE126306 | GEO

WT vs IFN-gamma treated bulk RNA-seq libraries of HSCs

Project description:WT vs IFN-gamma treated bulk RNA-seq libraries of HSCs

| PRJNA884310 | ENA

Transcriptome profiling of castration resistant prostate cancer cells treated with novel AR N-terminal inhibitor

Project description:Transcriptome profiling of castration resistant prostate cancer cells treated with novel AR N-terminal inhibitor

| PRJNA1064082 | ENA